Taxonomy

The 2019 Fall CMTA Report

The Type 2 Issue: We have set the stage for a number of Type 2 breakthroughs on our way to treatments for CMT.

New Gene Therapy, Type 1/Type 4 Research Projects Approved

The CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4.

New Gene Therapy Development Program for CMT2A

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).

$1 Million Gift Pledged to CMT Type 2 Research!

Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.

2019 Summer CMTA Report

All in the Family: The many branches of the CMTA family tree—the patients, the families that support them and the doctors who treat them.

Remembering Camp Footprint

Swim in a cool lake. Make a new friend. Practice archery or ride a horse. Remember what summer camp was like; then see what it was like at Camp Footprint, the only camp in the U.S. solely for kids with CMT.

Finding Friendship at Camp Footprint!

In her own words, Riley wants you to know why Camp Footprint has become her “most favorite week out of the entire year.”

Support Our Campers – Whatever It Takes!

"A free one week camp for kids with CMT? Wow! I just have to be part of this. I’ll do whatever it takes to get involved!”

Camp Help Falling in Love

Cooper’s first day at Camp Footprint was also the first day he learned what it's like NOT to have to explain his CMT when meeting other kids.

CMTA Unveils Updated Logo

The CMTA’s new logo, which we are revealing for the first time in the Spring 2019 issue of The CMTA Report, is only the third version in our 35-year history.